Functional characterization of α-Gal producing lactic acid bacteria with potential probiotic properties.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 05 2022
06 05 2022
Historique:
received:
01
01
2022
accepted:
27
04
2022
entrez:
6
5
2022
pubmed:
7
5
2022
medline:
11
5
2022
Statut:
epublish
Résumé
The possibility of exploiting the human immune response to glycan α-Gal for the control of multiple infectious diseases has been the objective of recent investigations. In this field of research, the strain of Escherichia coli O86:B7 has been at the forefront, but this Gram-negative microorganism presents a safety concern and therefore cannot be considered as a probiotic. To address this challenge, this study explored the identification of novel lactic acid bacteria with a safe history of use, producing α-Gal and having probiotic potential. The lactic acid bacteria were isolated from different traditionally fermented foods (kununn-zaki, kindirmo, and pulque) and were screened for the production of α-Gal and some specific probiotic potential indicators. The results showed that Ten (10) out of forty (40) [25%] of the tested lactic acid bacteria (LAB) produced α-Gal and were identified as Limosilactobacillus fermentum, Levilactobacillus brevis, Agrilactobacillus composti, Lacticaseibacillus paracasei, Leuconostoc mesenteroides and Weissella confusa. Four (4) LAB strains with highest levels of α-Gal were further selected for in vivo study using a mouse model (α1,3GT KO mice) to elucidate the immunological response to α-Gal. The level of anti-α-Gal IgG observed were not significant while the level of anti-α-Gal IgM was lower in comparison to the level elicited by E. coli O86:B7. We concluded that the lactic acid bacteria in this study producing α-Gal have potential probiotic capacity and can be further explored in α-Gal-focused research for both the prevention and treatment of various infectious diseases and probiotic development.
Identifiants
pubmed: 35524154
doi: 10.1038/s41598-022-11632-8
pii: 10.1038/s41598-022-11632-8
pmc: PMC9075922
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7484Informations de copyright
© 2022. The Author(s).
Références
PLoS One. 2007 Dec 12;2(12):e1308
pubmed: 18074031
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):644-645
pubmed: 32339473
Cell. 2014 Dec 4;159(6):1277-89
pubmed: 25480293
Int J Infect Dis. 2004 Jan;8(1):5-12
pubmed: 14690775
Vaccines (Basel). 2020 Jun 07;8(2):
pubmed: 32517302
Exp Mol Med. 2017 Mar 10;49(3):e301
pubmed: 28280265
N Engl J Med. 2021 Apr 22;384(16):1517-1528
pubmed: 33826814
Front Microbiol. 2019 Feb 26;10:300
pubmed: 30863379
Immunotherapy. 2021 Feb;13(3):185-188
pubmed: 33307805
Braz J Microbiol. 2021 Jun;52(2):869-881
pubmed: 33694058
Int J Food Microbiol. 2014 Nov 3;190:84-96
pubmed: 25203619
Int J Food Sci Nutr. 2012 May;63(3):278-82
pubmed: 21970387
PLoS One. 2018 Mar 8;13(3):e0192978
pubmed: 29518093
Nat Commun. 2020 May 25;11(1):2610
pubmed: 32451391
Trends Parasitol. 2015 Oct;31(10):470-476
pubmed: 26433250
Int J Syst Evol Microbiol. 2020 Apr;70(4):2782-2858
pubmed: 32293557
Vet World. 2020 Sep;13(9):1922-1927
pubmed: 33132606
Expert Rev Vaccines. 2016 Aug;15(8):953-5
pubmed: 27100121
Front Biosci (Landmark Ed). 2021 Aug 30;26(8):379-386
pubmed: 34455767
Front Immunol. 2017 Dec 04;8:1733
pubmed: 29255472
Blood. 1993 Oct 15;82(8):2485-93
pubmed: 7691263
Front Microbiol. 2019 Jun 28;10:1382
pubmed: 31316477
Front Immunol. 2021 Sep 08;12:730710
pubmed: 34566994
Pharmaceuticals (Basel). 2021 Jun 30;14(7):
pubmed: 34208966
Probiotics Antimicrob Proteins. 2021 Oct;13(5):1254-1266
pubmed: 33791994
Front Immunol. 2020 Jan 13;10:3000
pubmed: 31998300
Nat Prod Rep. 2020 Mar 25;37(3):338-354
pubmed: 31544193
Trends Parasitol. 2020 Dec;36(12):992-1001
pubmed: 32948455
Am J Phys Anthropol. 2019 Feb;168(2):352-363
pubmed: 30578545
Vet Sci. 2018 Jun 20;5(2):
pubmed: 29925800
Front Microbiol. 2014 Jun 12;5:254
pubmed: 24971076
Front Immunol. 2021 Jul 12;12:704621
pubmed: 34322135
J Immunol. 2020 Apr 1;204(7):1998-2005
pubmed: 32144163
Antibodies (Basel). 2020 Jun 22;9(2):
pubmed: 32580274
J Sci Food Agric. 2020 Jan 30;100(2):705-713
pubmed: 31599967
Braz J Med Biol Res. 2020 Jan 24;53(2):e8749
pubmed: 31994600
Microorganisms. 2021 Mar 19;9(3):
pubmed: 33808742
J Med Virol. 2021 Apr;93(4):2065-2075
pubmed: 33009829
J Genet Eng Biotechnol. 2018 Dec;16(2):357-362
pubmed: 30733746
Lancet Infect Dis. 2016 Feb;16(2):239-51
pubmed: 26795692
Annu Rev Immunol. 2014;32:157-87
pubmed: 24655294
Trends Parasitol. 2016 Feb;32(2):120-130
pubmed: 26774793
Nutrients. 2019 Aug 05;11(8):
pubmed: 31387262
Trends Parasitol. 2015 Jan;31(1):2-4
pubmed: 25532754
ACS Cent Sci. 2017 Nov 22;3(11):1140-1142
pubmed: 29202015
J Food Drug Anal. 2018 Jul;26(3):927-939
pubmed: 29976412
Appl Microbiol Biotechnol. 2016 Jan;100(1):385-396
pubmed: 26476654
J Infect. 2020 Jul;81(1):17-47
pubmed: 32035939
Vaccines (Basel). 2020 Apr 24;8(2):
pubmed: 32344637
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Vaccines (Basel). 2021 May 06;9(5):
pubmed: 34066443
PLoS Pathog. 2020 May 21;16(5):e1008556
pubmed: 32437478
Vaccines (Basel). 2020 Nov 21;8(4):
pubmed: 33233316